Genitourinary Cancers

Regular use of aspirin appeared to reduce the risk for dying from lethal prostate cancer in a large observational study reported at the 2016 Genitourinary Cancers Symposium. Read More ›

Docetaxel added to androgen-deprivation therapy (ADT) improves survival for men with metastatic hormone-sensitive prostate cancer (mHSPC), as shown by the pivotal ECOG 3805 CHAARTED trial. Read More ›

Men with low-risk prostate cancer are typically offered management with active surveillance, which entails regular office visits, digital rectal exam, MRI scans, prostate-specific antigen (PSA) testing, and prostate biopsy at physician-specified intervals. Read More ›

Two pilot programs aimed at reducing the utilization of in­appropriate testosterone replacement therapy, particularly in the treatment of men with age-related hypogonadism, have shown success in raising awareness of evidence and safety concerns. Read More ›

Although recent studies have shown the efficacy of using ster­eotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained. According to findings presented at the 2015 Genitourinary Cancers Symposium, those questions have been answered: the SBRT approach demonstrates acceptable urinary and sexual toxicity. Read More ›

Use of adjuvant sorafenib and sunitinib failed to extend disease-free survival (DFS) in patients with locally advanced kidney cancer at high risk of recurrence, according to initial results from the ASSURE study presented at the 2015 Genitourinary Cancers Symposium. ASSURE is the first and largest study of adjuvant vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors in kidney cancer. Read More ›

Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium suggests that the androgen receptor (AR) abnormality known as AR-V7 will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate cancer (CRPC). Read More ›

Many molecularly targeted agents that inhibit different pathways of hepatocarcinogenesis are under clinical development, and novel targets are being assessed in hepatocellular carcinoma (HCC). Read More ›

The rate of therapy for localized prostate cancer does not increase in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy (IMRT), according to an examination of trends using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. Read More ›

Abiraterone plus prednisone reduces the risk of disease progression and delays the time to opiate use and chemotherapy versus prednisone alone in men with metastatic castration-resistant prostate cancer (mCRPC) who had not received chemotherapy for metastatic disease. Read More ›